H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer

Pancreatic cancer is the eighth cancer leading cause of cancer-related death in the world and has a 5-year survival rate of 1–4% only. Gemcitabine is a first line agent for advanced pancreatic therapy; however, its efficacy is limited by its poor intracellular metabolism and chemoresistance. Studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorin, Vladimir, Ohana, Patricia, Gallula, Jennifer, Birman, Tatiana, Matouk, Imad, Hubert, Ayala, Gilon, Michal, Hochberg, Avraham, Czerniak, Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371723/
https://www.ncbi.nlm.nih.gov/pubmed/22701803
http://dx.doi.org/10.5402/2012/351750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371723/
https://www.ncbi.nlm.nih.gov/pubmed/22701803
http://dx.doi.org/10.5402/2012/351750

Ejemplares similares